ADCT vs. ANRO, ESPR, AMRN, FBLG, ATAI, NATR, ORGO, RANI, NKTX, and ANL
Should you be buying ADC Therapeutics stock or one of its competitors? The main competitors of ADC Therapeutics include Alto Neuroscience (ANRO), Esperion Therapeutics (ESPR), Amarin (AMRN), FibroBiologics (FBLG), Atai Life Sciences (ATAI), Nature's Sunshine Products (NATR), Organogenesis (ORGO), Rani Therapeutics (RANI), Nkarta (NKTX), and Adlai Nortye (ANL). These companies are all part of the "pharmaceutical preparations" industry.
ADC Therapeutics (NYSE:ADCT) and Alto Neuroscience (NYSE:ANRO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.
ADC Therapeutics currently has a consensus price target of $7.50, suggesting a potential upside of 72.81%. Alto Neuroscience has a consensus price target of $32.33, suggesting a potential upside of 128.67%. Given Alto Neuroscience's stronger consensus rating and higher possible upside, analysts plainly believe Alto Neuroscience is more favorable than ADC Therapeutics.
Alto Neuroscience has a net margin of 0.00% compared to ADC Therapeutics' net margin of -344.15%. Alto Neuroscience's return on equity of 0.00% beat ADC Therapeutics' return on equity.
41.1% of ADC Therapeutics shares are held by institutional investors. 35.4% of ADC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Alto Neuroscience has lower revenue, but higher earnings than ADC Therapeutics.
In the previous week, ADC Therapeutics and ADC Therapeutics both had 3 articles in the media. ADC Therapeutics' average media sentiment score of 0.26 beat Alto Neuroscience's score of 0.20 indicating that ADC Therapeutics is being referred to more favorably in the media.
ADC Therapeutics received 44 more outperform votes than Alto Neuroscience when rated by MarketBeat users. However, 100.00% of users gave Alto Neuroscience an outperform vote while only 64.10% of users gave ADC Therapeutics an outperform vote.
Summary
Alto Neuroscience beats ADC Therapeutics on 9 of the 14 factors compared between the two stocks.
Get ADC Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ADC Therapeutics Competitors List
Related Companies and Tools
